CoChat

Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Pharmacological blockade of the mineralocorticoid receptor (MR) ameliorates end-organ damage in chronic heart failure. However, the clinical use of available steroidal MR antagonists is restricted because of concomitant hyperkalemia especially in patients with diminished kidney function. We have recently identified a novel nonsteroidal MR antagonist, finerenone, which uniquely combines potency and selectivity toward MR. Here, we investigated the tissue distribution and chronic cardiorenal end-organ protection of finerenone in comparison to the steroidal MR antagonist, eplerenone, in 2 different preclinical rat disease models. Quantitative whole-body autoradiography revealed that [C]-labeled finerenone equally distributes into rat cardiac and renal tissues. Finerenone treatment prevented deoxycorticosterone acetate-/salt-challenged rats from functional as well as structural heart and kidney damage at dosages not reducing systemic blood pressure. Finerenone reduced cardiac hypertrophy, plasma prohormone of brain natriuretic peptide, and proteinuria more efficiently than eplerenone when comparing equinatriuretic doses. In rats that developed chronic heart failure after coronary artery ligation, finerenone (1 mg·kg·d), but not eplerenone (100 mg·kg·d) improved systolic and diastolic left ventricular function and reduced plasma prohormone of brain natriuretic peptide levels. We conclude that finerenone may offer end-organ protection with a reduced risk of electrolyte disturbances.

Overview

Integrity signals

Registry

Crossref · 10.1097/fjc.0000000000000091

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 28 references

Research works printed but not linked: 3

  1. Delcayre, 1999, 43, 7
  2. Bauersachs, 2013, 34, 2426
  3. Platt, 1972, Arzneimittelforschung, 22, 1801

Cited by

See all 449

Metadata

Authors
Kolkhof, P., Delbeck, M., Kretschmer, A., Steinke, W., Hartmann, E., Bärfacker, L., Eitner, F., Albrecht-Küpper, B., & Schäfer, S.
Affiliations
Bayer (Germany) (DE)
Corresponding author
  • Kolkhof, Peter
  • Delbeck, Martina
  • Eitner, Frank
  • Albrecht-Küpper, Barbara
Venue
Journal of Cardiovascular Pharmacology
Published
2014-07
Volume
64
Issue
1
Pages
69-78
ISSN
0160-2446 (ISSN-L)
OpenAlex
W2079169053
Cited by
430
References
28
Citations by year
2026: 59 · 2025: 52 · 2024: 45 · 2023: 50 · 2022: 60 · 2021: 37 · 2020: 21 · 2019: 26 · 2018: 12 · 2017: 21 · 2016: 19 · 2015: 24 · 2014: 4
FWCI
18.24
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Cardiovascular Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
European Society of Cardiology
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
finerenone, mineralocorticoid receptor antagonists, eplerenone, cardiorenal protection, chronic heart failure, cardiac hypertrophy, proteinuria, brain natriuretic peptide, left ventricular function, tissue distribution, hyperkalemia, coronary artery ligation, desoxycorticosterone acetate, salt loading, chronic kidney disease
MeSH terms
Eplerenone, Mineralocorticoid Receptor Antagonists, Animals, Autoradiography, Disease Models, Animal, Cardiomegaly, Heart Failure, Kidney Diseases, Male, Naphthyridines, Peptide Fragments, Spironolactone, Tissue Distribution, Rats, Sprague-Dawley, Rats, Wistar, Natriuretic Peptide, Brain, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury. https://app.cochat.ai/papers/10.1097/fjc.0000000000000091
The paper
Kolkhof, P., Delbeck, M., Kretschmer, A., Steinke, W., Hartmann, E., Bärfacker, L., Eitner, F., Albrecht-Küpper, B., & Schäfer, S. (2014). Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury. Journal of Cardiovascular Pharmacology. https://doi.org/10.1097/fjc.0000000000000091

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.